Pasithea Therapeutics Corp. has received IND clearance by the FDA to evaluate PAS-004, a small-molecule allosteric inhibitor of MEK 1/2, in patients with MAPK pathway-driven advanced solid tumors with ...
ABM Therapeutics Inc. presented a novel small-molecule, ATP-uncompetitive, phosphorylated MEK (pMEK) inhibitor – ABM-4095 – that potently prevents phosphorylation of MEK by RAF with moderate ...
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the ...